DA
DAP.F Danaher Corporation
- Market cap
- EUR 151B
- P/E
- 40.9x
- P/B
- 3.10x
- ROE
- 7.8%
- Dividend yield
- 0.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DAP.F undervalued?
Graham numberDAP.F trades 137.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Danaher Corporation fundamental analysis
No fundamental analysis for Danaher Corporation yet.
Danaher Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development…
Full company profileDanaher Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Danaher Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 16.9B | 18.3B | 19.9B | 17.9B | 22.3B | 29.5B | 31.5B | 23.9B | 23.9B | 24.6B | 25.0B |
| Gross Profit | 9.33B | 10.2B | 11.1B | 9.98B | 12.5B | 18.0B | 18.9B | 14.0B | 14.2B | 14.5B | 14.7B |
| Operating Income | 2.75B | 3.02B | 3.40B | 3.27B | 4.23B | 7.47B | 8.69B | 5.20B | 4.86B | 4.69B | 4.95B |
| EBITDA | - | 4.34B | 4.76B | 4.60B | 6.55B | 10.0B | 10.7B | 7.50B | 7.28B | 6.95B | 7.68B |
| Net Income | 2.55B | 2.49B | 2.65B | 3.01B | 3.65B | 6.43B | 7.21B | 4.76B | 3.90B | 3.61B | 4.18B |
| EPS | - | 3.58 | 3.78 | 4.33 | 5.13 | 9.00 | 9.90 | 6.44 | 5.42 | 5.11 | 5.94 |
| Balance Sheet | |||||||||||
| Total Assets | 45.3B | 46.6B | 47.8B | 62.1B | 76.2B | 83.2B | 84.4B | 84.5B | 77.5B | 83.5B | 93.3B |
| Total Liabilities | 22.2B | 20.3B | 19.6B | 31.8B | 36.4B | 38.0B | 34.3B | 31.0B | 28.0B | 30.9B | 39.6B |
| Shareholders' Equity | 23.0B | 26.4B | 28.2B | 30.3B | 39.8B | 45.2B | 50.1B | 53.5B | 49.5B | 52.5B | 53.6B |
| Cash & Short-term Investments | 964M | 630M | 788M | 19.9B | 6.04B | 2.59B | 6.00B | 5.86B | 2.08B | 4.62B | 5.68B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.52B | 3.48B | 4.02B | 3.95B | 6.21B | 8.36B | 8.52B | 8.09B | 6.69B | 6.42B | 6.32B |
| Capital Expenditure | 590M | 571M | 584M | 636M | 791M | 1.29B | 1.15B | 1.31B | 1.39B | 1.16B | 1.01B |
| Free Cash Flow | - | 2.86B | 3.37B | 3.32B | 5.42B | 7.06B | 7.37B | 6.78B | 5.30B | 5.26B | 5.31B |
| Ratios | |||||||||||
| ROE | 11.1% | 9.5% | 9.4% | 9.9% | 9.2% | 14.2% | 14.4% | 8.9% | 7.9% | 6.9% | 7.8% |
| ROA | 5.6% | 5.3% | 5.5% | 4.8% | 4.8% | 7.7% | 8.5% | 5.6% | 5.0% | 4.3% | 4.5% |
| Net Profit Margin | 15.1% | 13.6% | 13.3% | 16.8% | 16.4% | 21.8% | 22.9% | 19.9% | 16.3% | 14.7% | 16.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Danaher Corporation dividends
- Dividend yield
- 0.68%
- Forward dividend
- 1.43 EUR
- Payout ratio
- 24.3%
- Ex-dividend date
- Sep 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 878M | 1.24 | 24.3% |
| 2024 | USD 768M | 1.07 | 19.7% |
| 2023 | USD 824M | 1.11 | 17.3% |
| 2022 | USD 818M | 1.12 | 11.3% |
| 2021 | USD 742M | 1.04 | 11.5% |
| 2020 | USD 615M | 0.86 | 16.9% |
| 2019 | USD 527M | 0.76 | 17.5% |
| 2018 | USD 433M | 0.62 | 16.3% |
| 2017 | USD 378M | 0.54 | 15.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on May 21, 2004.
Who owns Danaher Corporation
- Insiders 10.82%
- Institutions 84.70%
- Public & others 4.48%
- Shares outstanding 704M
- Free float 626M
Danaher Corporation company profile
- Company name
- Danaher Corporation
- Ticker
- DAP.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58,000
- Fiscal year end
- December
- Address
- 2200 Pennsylvania Avenue N.W., Washington, DC, United States, 20037-1701
- Phone
- 202 828 0850
- Website
- danaher.com
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Danaher Corporation management
10- Mr. Steven M. RalesCo-Founder & Chairman · born 1951
- Ms. Julie Sawyer MontgomeryPresident, CEO & Director · born 1972
- Mr. Mitchell P. RalesCo-Founder & Director · born 1957
- Dr. Jose-Carlos Gutierrez-Ramos Ph.D.Senior VP & Chief Science Officer · born 1962
- Mr. Matthew R. McGrewExecutive Vice President · born 1972
- Mr. Rainer M. BlairSenior Advisor · born 1964
- Mr. Christopher Paul RileyExecutive VP of Biotechnology Group & CEO of Cytiva · born 1974
- Mr. Matthew E. Gugino C.F.A., CPAExecutive VP & CFO · born 1983
- Mr. Christopher M. BoudaVP & Chief Accounting Officer
- Ms. Rachel Marie Vatnsdal OlsonVice President of Investor Relations